Lv5
830 积分 2022-10-11 加入
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
3天前
已完结
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial
1个月前
已关闭
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition
3个月前
已完结
What's Next for Sotorasib in NSCLC?
11个月前
已完结
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
1年前
已完结
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision
1年前
已完结
The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
1年前
已完结
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases
1年前
已关闭
Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis
1年前
已关闭
皖公网安备34019202002308
